Tag: Halozyme Therapeutics

Halozyme to Report Second Quarter 2025 Financial and Operating Results

SAN DIEGO, July 22, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2025 financial and...

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO,...

- A word from our sponsors -

HomeTagsHalozyme Therapeutics

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven...

Nissan AMIEO Completes 180-Market Pricing Transformation with Syncron, Ahead of Schedule

MILESEEY Tools und magicplan geben strategische Partnerschaft bekannt und stellen gemeinsames Co-Branding S50R-Lasermessset vor

Tag: Halozyme Therapeutics

Halozyme to Report Second Quarter 2025 Financial and Operating Results

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Explore

Press Releases

News & Opinion

Living

Others

Follow us